By using a chimeric Ad5/F35 adenoviral vector, they successfully delivered the CRISPR/Cas9 system to human CD4+ T cells, efficiently silencing CCR5 expression and protecting these cells against HIV-1 infection with minimal off-target effects [79]. Here, CCR5 is linked to HIV-1 infection.